AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 2,400 ACUT shares in the open market. This brings his total holding to 6,502,400 shares.

About AccuStem

AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.

For more information, please visit www.accustem.com.

Investor and Media Contact:
Wendy Blosser
Email: [email protected]

You May Also Be Interested In

• San Joaquin Valley College Hosts Skilled Trades Night
• Esker Appoints Breanna Baker as Global Chief Sales Officer
• My Adult Doctor™ Launches Nationwide Virtual Healthcare Platform Expanding 24/7 Urgent Care, Primary Care, Wellness, and Advanced Digital and AI Health Services Across All 50 States, Puerto Rico, an